• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Virol Methods . Comparative study between virus neutralisation testing and other serological methods detecting anti-SARS-CoV-2 antibodies in Europ

tetano

Editor, Senior Moderator
J Virol Methods


. 2023 Sep 29;114825.
doi: 10.1016/j.jviromet.2023.114825. Online ahead of print. Comparative study between virus neutralisation testing and other serological methods detecting anti-SARS-CoV-2 antibodies in Europe, 2021

Ramona Mögling[SUP] 1 [/SUP], Johan Reimerink[SUP] 2 [/SUP], Kamelia R Stanoeva[SUP] 2 [/SUP], Maria Keramarou[SUP] 3 [/SUP], Raquel Guiomar[SUP] 4 [/SUP], Inês Costa[SUP] 4 [/SUP], Anu Haveri[SUP] 5 [/SUP], Barbara Holzer[SUP] 6 [/SUP], Gülay Korukluoğlu[SUP] 7 [/SUP], Trung Nguyen[SUP] 8 [/SUP], Gatis Pakarna[SUP] 9 [/SUP], Katarzyna Pancer[SUP] 10 [/SUP], Katarina Prosenc Trilar[SUP] 11 [/SUP], Jelena Protic[SUP] 12 [/SUP], Marijana Stojanović[SUP] 12 [/SUP], Riccardo De Santis[SUP] 13 [/SUP], Florigio Lista[SUP] 13 [/SUP], Teodora Vremera[SUP] 14 [/SUP], Mihaela Leustean[SUP] 14 [/SUP], Adriana Pistol[SUP] 14 [/SUP], Hana Zelena[SUP] 15 [/SUP], Chantal Reusken[SUP] 2 [/SUP], Eeva K Broberg[SUP] 3 [/SUP]



Affiliations
Abstract

One consequence of the ongoing coronavirus disease pandemic was the rapid development of both in-house and commercial serological assays detecting anti-SARS-CoV-2 antibodies, in an effort to reliably detect acute and past SARS-CoV-2 infections. It is crucial to evaluate the quality of these serological tests and consequently the sero-epidemiological studies that are performed with the respective tests. Here, we describe the set-up and results of a comparative study, in which a laboratory contracted by the European Centre for Disease Prevention and Control offered a centralised service to EU/EEA Member and pre-accession Member States to test representative serum specimens with known serological results, with the gold standard technique (virus neutralisation tests) to determine the presence of neutralising antibodies. Laboratories from 12 European countries shared 719 serum specimens with the contractor laboratory. We found that in-house serological tests detecting neutralising antibodies showed the highest percent agreement, both positive and negative, with the virus neutralisation test results. Despite extensive differences in virus neutralisation protocols neutralisation titres showed a strong correlation. From the commercial assays, the best positive percent agreement was found for SARS-CoV-2 IgG (sCOVG) (Siemens - Atellica IM Analyzer). Despite lower positive percent agreement of LIAISON SARS-CoV-2 TrimericS IgG kit (Diasorin Inc.), the obtained results showed relatively good correlation with neutralisation titres. The set-up of this study allowed for high comparability between laboratories and enabled laboratories that do not have the capacity or capability to perform VNTs themselves. Given the variety of in-house protocols detecting SARS-CoV-2 specific neutralising antibodies, including the virus strain, it could be of interest to select reference isolates for SARS-CoV-2 diagnostic to be made available for interested EU Member States and pre-accession countries.

Keywords: COVID-19; Europe; SARS-CoV-2; serology; virus neutralisation.

 
Back
Top Bottom